Global CNS market set to decline, but will see launch of multiple anti-Alzheimer's drugs in Japan

Valued at $84.4 billion, the central nervous system (CNS) disorders market posted a growth of 7.9% over the previous year. Market expansion was primarily driven by the growth in sales from CNS disorders such as Alzheimer's disease, epilepsy and attention-deficit hyperactivity disorder (ADHD), according to a new report from Business Insights.

Business Insights anticipates the market to decline at a compound annual growth rate (CAGR) of 5.2% to $61.3 billion sales in 2014 due several drug classes experiencing 'genericization.' For instance, in the antipsychotics drug class, patent expirations of key brands Seroquel (quetiapine) and Zyprexa (olanzapine) are likely to be the key resistors to segmental growth through this period.

The CNS disorders market may be segmented into numerous subcategories, including major depressive disorder (MDD), epilepsy, schizophrenia, Alzheimer's disease (AD), Parkinson's disease (PD), migraine, insomnia, attention-deficit hyperactivity disorder (ADHD), bipolar disorder among others. While established treatments are currently available for each of these therapeutic subcategories, these markets are large and significant unmet medical needs still remain, says Business Insights. Novel treatments under development seek to address these opportunities.